An outcome model approach to transporting a randomized controlled trial results to a target population
暂无分享,去创建一个
Elizabeth A. Stuart | Michael J. Pencina | Benjamin A. Goldstein | Matthew Phelan | Neha J. Pagidipati | Rury R. Holman | E. Stuart | M. Pencina | R. Holman | B. Goldstein | N. Pagidipati | Matthew Phelan
[1] Yangxin Huang,et al. Generalizability analysis for clinical trials: a simulation study , 2017, Statistics in medicine.
[2] S. Cole,et al. Correction: Sensitivity analysis for an unobserved moderator in RCT-to-target-population generalization of treatment effects , 2016, The Annals of Applied Statistics.
[3] Shuang Wang,et al. Assessing the Collective Population Representativeness of Related Type 2 Diabetes Trials by Combining Public Data from ClinicalTrials.gov and NHANES , 2015, MedInfo.
[4] M. Flather,et al. Generalizing results of randomized trials to clinical practice: reliability and cautions , 2006, Clinical trials.
[5] M. Kivimäki,et al. Risk of Cardiovascular Disease and Death in Individuals With Prediabetes Defined by Different Criteria: The Whitehall II Study , 2018, Diabetes Care.
[6] J. Johnston,et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results , 2015, Trials.
[7] Sarah E. Robertson,et al. Generalizing causal inferences from individuals in randomized trials to all trial‐eligible individuals , 2017, Biometrics.
[8] S. Cole,et al. Generalizing Randomized Clinical Trial Results: Implementation and Challenges Related to Missing Data in the Target Population , 2018, American journal of epidemiology.
[9] S. Cole,et al. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. , 2010, American journal of epidemiology.
[10] Jennifer Hill,et al. Assessing Methods for Generalizing Experimental Impact Estimates to Target Populations , 2016, Journal of research on educational effectiveness.
[11] Mark McClellan,et al. Implementing MACRA: Implications for Physicians and for Physician Leadership. , 2016, JAMA.
[12] G Hripcsak,et al. A Distribution-based Method for Assessing The Differences between Clinical Trial Target Populations and Patient Populations in Electronic Health Records , 2014, Applied Clinical Informatics.
[13] Angela M Wood,et al. The use of repeated blood pressure measures for cardiovascular risk prediction: a comparison of statistical models in the ARIC study , 2016, Statistics in medicine.
[14] M. Laakso,et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.
[15] Udaya B. Kogalur,et al. Random Survival Forests for R , 2007 .
[16] R. Califf,et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. , 2008, American heart journal.
[17] W. Hohenberger,et al. Differences Between Clinical Trial Participants and Patients in a Population-Based Registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry , 2009, Diseases of the colon and rectum.
[18] M. Laakso,et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.
[19] Elizabeth A Stuart,et al. Generalizability of Randomized Trial Results to Target Populations , 2018, Research on social work practice.
[20] Eloise E Kaizar,et al. The use of propensity scores and observational data to estimate randomized controlled trial generalizability bias , 2013, Statistics in medicine.
[21] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[22] Chunhua Weng,et al. Sick Patients Have More Data: The Non-Random Completeness of Electronic Health Records , 2013, AMIA.
[23] Benjamin A. Goldstein,et al. Illustrating Informed Presence Bias in Electronic Health Records Data: How Patient Interactions with a Health System Can Impact Inference , 2017, EGEMS.
[24] Marie Lynn Miranda,et al. Geographic health information systems: a platform to support the 'triple aim'. , 2013, Health affairs.
[25] Michael G Hudgens,et al. Generalizing evidence from randomized trials using inverse probability of sampling weights , 2018, Journal of the Royal Statistical Society. Series A,.
[26] Stefan Wager,et al. Estimation and Inference of Heterogeneous Treatment Effects using Random Forests , 2015, Journal of the American Statistical Association.
[27] Hemant Ishwaran,et al. Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.
[28] Hans-Ulrich Prokosch,et al. Evaluation of data completeness in the electronic health record for the purpose of patient recruitment into clinical trials: a retrospective analysis of element presence , 2013, BMC Medical Informatics and Decision Making.
[29] Hemant Ishwaran,et al. Estimating Individual Treatment Effect in Observational Data Using Random Forest Methods , 2017, Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America.
[30] Michael J Pencina,et al. A comparison of risk prediction methods using repeated observations: an application to electronic health records for hemodialysis. , 2017, Statistics in medicine.
[31] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[32] Zab Mosenifar,et al. Population issues in clinical trials. , 2007, Proceedings of the American Thoracic Society.
[33] Stephen R Cole,et al. Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.
[34] Catherine P. Bradshaw,et al. The use of propensity scores to assess the generalizability of results from randomized trials , 2011, Journal of the Royal Statistical Society. Series A,.
[35] D. Rubin,et al. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score , 1985 .